Comprehensive microRNA Profiling of Prostate Cancer
暂无分享,去创建一个
Peter A. Pinto | M. Merino | P. Pinto | Maria J. Merino | Vladimir A. Valera | Beatriz A. Walter | B. Walter | V. Valera | M. Merino
[1] Y. Asmann,et al. miRNA Expression in Colon Polyps Provides Evidence for a Multihit Model of Colon Cancer , 2011, PloS one.
[2] A. Eklund,et al. MicroRNA profile analysis of human prostate cancers , 2009, Cancer Gene Therapy.
[3] L. Sempere. Integrating contextual miRNA and protein signatures for diagnostic and treatment decisions in cancer , 2011, Expert review of molecular diagnostics.
[4] L. Selth,et al. Circulating microRNAs: macro-utility as markers of prostate cancer? , 2012, Endocrine-related cancer.
[5] C. Tepper,et al. microRNAs and prostate cancer , 2008, Journal of cellular and molecular medicine.
[6] Aamir Ahmad,et al. Recent updates on the role of microRNAs in prostate cancer , 2012, Journal of Hematology & Oncology.
[7] Lang Li,et al. Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate , 2004, Cancer.
[8] W. Fair,et al. Prognostic significance of antigenic heterogeneity, gleason grade, and ploidy of lymph node metastases in patients with prostate cancer , 1992, The Prostate.
[9] K. Junker,et al. Specific protein and miRNA patterns characterise tumour-associated fibroblasts in bladder cancer , 2011, Journal of Cancer Research and Clinical Oncology.
[10] Hong-zhao Li,et al. Differential miRNA expression profiles in bladder urothelial carcinomas. , 2010, Asian Pacific journal of cancer prevention : APJCP.
[11] D. Wood,et al. Gleason histologic grading in prostatic carcinoma. Correlation of 18-gauge core biopsy with prostatectomy. , 1994, Archives of pathology & laboratory medicine.
[12] S. Fosså,et al. Prognostic significance of histologic grading in patients with prostate carcinoma who are assessed by the Gleason and World Health Organization grading systems in needle biopsies obtained prior to radiotherapy , 2001, Cancer.
[13] P. Carroll,et al. Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. , 1994, International journal of radiation oncology, biology, physics.
[14] C. Creighton,et al. Widespread deregulation of microRNA expression in human prostate cancer , 2008, Oncogene.
[15] H. Horvitz,et al. MicroRNA expression profiles classify human cancers , 2005, Nature.
[16] A. Seth,et al. MicroRNAs in prostate cancer: from biomarkers to molecularly-based therapeutics , 2012, Prostate Cancer and Prostatic Diseases.
[17] U. Capitanio,et al. Radical prostatectomy represents an effective treatment in patients with specimen‐confined high pathological Gleason score prostate cancer , 2013, BJU international.
[18] C. Croce,et al. MicroRNAs in the pathogenesis of cancer. , 2011, Seminars in oncology.
[19] C. Croce,et al. A microRNA expression signature of human solid tumors defines cancer gene targets , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[20] T. Stamey,et al. Biological determinants of cancer progression in men with prostate cancer. , 1999, JAMA.
[21] M. Ferracin,et al. MicroRNAs: toward the clinic for breast cancer patients. , 2011, Seminars in oncology.
[22] O. Brawley. Prostate cancer epidemiology in the United States , 2012, World Journal of Urology.
[23] R. Mantovani,et al. miR-205 regulates basement membrane deposition in human prostate: implications for cancer development , 2012, Cell Death and Differentiation.
[24] C. Stephan,et al. Diagnostic, prognostic and therapeutic implications of microRNAs in urologic tumors , 2010, Nature Reviews Urology.